1. Urinary prostaglandin D2 and E2 metabolites are elevated with disease severity in patients with Fukuyama congenital muscular dystrophy
- Author
-
Keiko Ishigaki, Atsuko Takeuchi, Mariko Taniguchi-Ikeda, Takatoshi Sato, Terumi Murakami, Minobu Shichiji, Kumiko Ishiguro, Yuki Kihara, Satoru Nagata, and Yoshihiro Urade
- Subjects
Fukuyama congenital muscular dystrophy ,Prostaglandin D2 ,Prostaglandin E2 ,tetranor-PGDM ,tetranor-PGEM ,Medicine ,Science - Abstract
Abstract Treatment approaches are lacking for Fukuyama congenital muscular dystrophy (FCMD), the second most common type of pediatric muscular dystrophy after Duchenne muscular dystrophy (DMD) in the Japanese population. Recent studies demonstrating the involvement of prostaglandin (PG) D2 in DMD progression has led to the development of novel inhibitors targeting hematopoietic PGD2 synthase. This study aimed to determine the role of PGD2 in FCMD etiology in 42 patients with FCMD and 77 healthy age-matched individuals. Concentrations of tetranor-PGDM and tetranor-PGEM, the metabolites of PGD2 and PGE2, respectively, and creatinine were measured in spot urine samples. Mean tetranor-PGDM/creatinine and tetranor-PGEM/creatinine concentrations and tetranor-PGEM/tetranor-PGDM ratio were significantly higher in patients with FCMD than the healthy controls (5.3 ± 2.1 and 30.9 ± 52.3 ng/mg creatinine and 6.8 ± 2.0 vs. 3.4 ± 0.3 and 9.5 ± 0.9 ng/mg creatinine and 3.2 ± 0.3, respectively; p = 0.0011, p
- Published
- 2025
- Full Text
- View/download PDF